Spectral AI, Inc. (MDAIW) Aandelenanalyse

Bedrijfsoverzicht

Spectral AI, Inc. is a specialized entity focused on artificial intelligence applications within the United States, specifically targeting predictive medical diagnostics. The company's core offering, the DeepView System, utilizes proprietary algorithms to analyze tissue characteristics, distinguishing between fully damaged, partially damaged, and healthy human tissue. Although the specific sector and industry classifications are not publicly disclosed in available data, the firm operates within the high-tech healthcare infrastructure space. Spectral AI, Inc. maintains a workforce of 65 employees and reports a trailing twelve-month revenue of $19.65 million. The reported market capitalization is not currently available for calculation, which suggests the company may be in a pre-profitability stage or utilizes an alternative valuation model common for early-stage biotech and AI firms. The annual revenue figure of $19.65 million indicates that while the company has generated significant top-line sales to support its R&D operations, it faces substantial headwinds as indicated by its recent revenue contraction. The absence of a reported market cap alongside a negative price-to-book ratio highlights the speculative nature of its valuation, where investors are pricing in future technological breakthroughs rather than current earnings power.

Financiële gezondheid

Over the trailing twelve months, Spectral AI, Inc. generated revenue of $19.65 million but recorded a net income loss of $7,571,000, alongside an EBITDA of $-8,532,000. The significant gap between the positive revenue of $19.65 million and the negative net income of $7,571,000 reveals a cost structure dominated by high operating expenses, likely driven by research and development costs and the proprietary nature of the DeepView System. The company generated a free cash flow of $-1,379,875, indicating a net outflow of cash that limits immediate financial flexibility and necessitates reliance on external capital or cash reserves to fund operations. Despite the negative operating performance, the company holds a cash balance of $15.39 million against total debt of $10.09 million, providing a net cash position that offers a buffer against liquidity risks. The gross margin stands at 45.4%, which is a healthy indicator of pricing power or high-value software delivery, yet the operating margin is -54.9% and the profit margin is -38.5%, signaling that overhead costs and R&D expenditures are currently eroding a substantial portion of gross profits. The current ratio is 0.94, suggesting that current assets are slightly below current liabilities, which indicates a tight short-term liquidity position that requires careful management of working capital. The return on equity is not available for calculation, while the return on assets is -32.1%, which reveals that the company's asset base is generating a negative return on the capital employed.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E ratio are both not available, which implies that without positive earnings, traditional valuation multiples based on profitability cannot be applied to assess the trajectory of future earnings. The price-to-book ratio is reported at -3.10, a negative figure that indicates the market values the company's equity at less than zero relative to its book value, a metric often seen in distressed or pre-revenue biotechnology firms. The price-to-sales ratio is not available for disclosure, and the EV/EBITDA metric is also not available, meaning alternative valuation metrics that rely on profitability or enterprise value leverage are currently inapplicable for Spectral AI, Inc. The stock has a 52-week high of $0.58 and a 52-week low of $0.58, meaning the current trading price is exactly at the 52-week high and low, showing no price movement over the last year. The beta value is 0.91, which indicates that the stock's price volatility is roughly equal to the broader market, suggesting it does not amplify market movements significantly during periods of instability.

Growth & Income

Revenue growth year-over-year is -46.3%, while earnings growth year-over-year is not available due to the lack of profitable earnings history. Since the company is reporting a net loss, the concept of earnings growing faster than revenue does not apply in a traditional sense, as the primary financial focus is on achieving profitability rather than expanding earnings per share. Spectral AI, Inc. does not pay a dividend, evidenced by the non-existent dividend yield and payout ratio, which means the company reinvests any available capital or relies on external financing to fund its expansion and R&D initiatives rather than returning cash to shareholders. The overall growth and income profile is characterized by a significant contraction in revenue and a complete absence of income generation, reflecting a company that is still in a development phase where capital preservation is balanced against the pursuit of technological milestones in predictive medical diagnostics.